According to the American College of Gastroenterology (ACG) and the American Gastroenterology Association (AGA), screening is strongly recommended only in patients with hereditary syndromes (Peutz–Jeghers syndrome, hereditary pancreatitis, familial atypical multiple mole melanoma) and individuals of familial pancreatic cancer kindreds whose first-degree relative was diagnosed with pancreatic cancer, as well as mutation carriers from BRCA1, BRCA2, PALB2, ATM and Lynch syndrome families, with a first- or second-degree relative diagnosed with the disease [21,22]. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.